BioHarvest sets Q1 2026 earnings call for May 14
BioHarvest Sciences Inc. filed a Form 6-K announcing it will release its first quarter 2026 financial results before the market opens on May 14, 2026.
Rhea-AI Filing Summary
BioHarvest Sciences Inc. filed a Form 6-K announcing it will release its first quarter 2026 financial results before the market opens on May 14, 2026. The company will hold a conference call and live webcast at 8:00 a.m. U.S. Eastern Time to review results and provide a business update.
BioHarvest describes itself as a leader in Botanical Synthesis, using a patented platform to grow plant-based compounds without cultivating the full plant. It operates as a CDMO for novel plant-based compounds and develops proprietary nutraceutical health and wellness products, including dietary supplements.
Positive
- None.
Negative
- None.
Key Figures
Form type: Form 6-K
Earnings release date: May 14, 2026
Earnings call time: 8:00 a.m. U.S. Eastern Time
3 metrics
Form type
Form 6-K
Report of foreign private issuer for April 2026
Earnings release date
May 14, 2026
First quarter 2026 financial results
Earnings call time
8:00 a.m. U.S. Eastern Time
Q1 2026 results conference call and webcast
Key Terms
Form 6-K, foreign private issuer, Botanical Synthesis, contract development and manufacturing organization (CDMO), +1 more
5 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Botanical Synthesis technical
"a leader in Botanical Synthesis, leveraging its patented technology platform"
Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.
contract development and manufacturing organization (CDMO) financial
"as a contract development and manufacturing organization (CDMO) on behalf of customers"
A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.
forward-looking statements regulatory
"Information set forth in this news release might include forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
When will BioHarvest Sciences (BHST) report Q1 2026 financial results?
BioHarvest Sciences will report its first quarter 2026 financial results before the market opens on May 14, 2026. The company will pair the release with a conference call and webcast to discuss results and provide an update on business operations.
What time is BioHarvest Sciences (BHST) Q1 2026 earnings call?
The Q1 2026 earnings conference call for BioHarvest Sciences is scheduled for 8:00 a.m. U.S. Eastern Time on May 14, 2026. A live webcast will be available, and a recording will later be posted in the Investor Relations/Events & Presentations section.
How can investors access the BioHarvest Sciences (BHST) Q1 2026 earnings webcast?
Investors can access the BioHarvest Sciences Q1 2026 earnings webcast through the provided webcast link and are encouraged to register at least 10 minutes before the 8:00 a.m. Eastern Time start. A replay will be available on the company’s website under Investor Relations/Events & Presentations.
What does BioHarvest Sciences (BHST) do in Botanical Synthesis?
BioHarvest Sciences uses a patented Botanical Synthesis platform to grow plant-based compounds without cultivating the underlying plant. The company applies this technology as a CDMO for customers seeking novel plant-based compounds and to create proprietary nutraceutical health and wellness products, including dietary supplements.
What forward-looking statement cautions does BioHarvest Sciences (BHST) provide?
BioHarvest notes its news release may contain forward-looking statements based on current estimates and subject to risks and uncertainties. It cautions readers not to place undue reliance on such statements and refers to Risk Factors in its SEC filings available on its website and the SEC’s site.
Which stock exchanges list BioHarvest Sciences (BHST)?
BioHarvest Sciences is listed on NASDAQ under the ticker BHST and on the Frankfurt Stock Exchange under the symbol 8MV0 or 8MV. These listings support access for investors in North America and Europe interested in the company’s Botanical Synthesis business model.
AI-generated analysis. How Rhea-AI works. Not financial advice.
